
4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema
4D Molecular Therapeutics announced the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME).1 David Kirn, MD, co-founder and CEO of 4DMT …